Trials / Completed
CompletedNCT00099255
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-30 |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2004-12-10
- Last updated
- 2014-12-18
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00099255. Inclusion in this directory is not an endorsement.